In last trading session, Taysha Gene Therapies Inc (NASDAQ:TSHA) saw 1.4 million shares changing hands with its beta currently measuring 0.35. Company’s recent per share price level of $2.42 trading at -$0.01 or -0.41% at ring of the bell on the day assigns it a market valuation of $452.59M. That closing price of TSHA’s stock is at a discount of -60.74% from its 52-week high price of $3.89 and is indicating a premium of 79.34% from its 52-week low price of $0.50. Taking a look at company’s average trading volume volume of 2.80 million if we extend that period to 3-months.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Upright in the red during last session for losing -0.41%, in the last five days TSHA remained trading in the green while hitting it’s week-highest on Monday, 04/29/24 when the stock touched $2.42 price level, adding 6.92% to its value on the day. Taysha Gene Therapies Inc’s shares saw a change of 36.72% in year-to-date performance and have moved 2.98% in past 5-day. Taysha Gene Therapies Inc (NASDAQ:TSHA) showed a performance of -10.70% in past 30-days.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
Statistics highlight that Taysha Gene Therapies Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 7.08% of value to its shares in past 6 months, showing an annual growth rate of 59.38% while that of industry is 22.10. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 60.70% in the current quarter and calculating 71.10% increase in the next quarter. This year revenue growth is estimated to fall -33.70% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $2.56 million for the same. And 9 analysts are in estimates of company making revenue of $2.57 million in the next quarter that will end on Jun 2024. Company posted $4.71 million and $2.4 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -45.60% while estimating it to be 7.30% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -137.69% during past 5 years.
TSHA Dividends
Taysha Gene Therapies Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
